TWA
RNAC icon

TCI Wealth Advisors’s Cartesian Therapeutics RNAC Stock Holding History

TCI Wealth Advisors’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-3
Closed – – 1648
2020
Q3 		$0 Sell
3
-7
-70% -$536 ﹤0.01% 1642
2020
Q2 		$1K Hold
10
– – ﹤0.01% 1336
2020
Q1 		$1K Buy
+10
New +$965 ﹤0.01% 1326

Other funds holding RNAC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

TCI Wealth Advisors's RNAC Position: Q4 2020 in Review

TCI Wealth Advisors sold out of Cartesian Therapeutics (RNAC) in Q4 2020, closing a stake of 3 shares.

TCI Wealth Advisors first reported a position in RNAC in Q1 2020 and held it in 3 quarters. The position peaked at $1K in Q2 2020. 95 funds tracked by Wall St. Rank hold RNAC as of Q4 2020.

  • TCI Wealth Advisors reported no remaining Cartesian Therapeutics position as of Q4 2020 after selling out during the quarter.
  • TCI Wealth Advisors sold 3 Cartesian Therapeutics shares in Q4 2020.
  • TCI Wealth Advisors first reported a position in Cartesian Therapeutics in Q1 2020 and held it in 3 quarters.
  • TCI Wealth Advisors's Cartesian Therapeutics position peaked at $1K in Q2 2020.
  • 95 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2020.

Based on TCI Wealth Advisors's 13F filing for Q4 2020, filed 21 Jan 2021.